A Phase 2 interventional study of APG777 and APG777 in Atopic Dermatitis, sponsored by Apogee Therapeutics, Inc.. Recruiting at 80 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Apogee Therapeutics, Inc. (part of AbbVie) · Phase 2, Interventional, and Treatment
This is a multicenter, double-blind, Long-Term Extension (LTE) study to evaluate the long-term safety and efficacy of APG777 in patients with moderate-to-severe AD who have completed treatment in an APG777 Parent Study (NCT06395948).
The LTE study will consist of 3 periods: 1) Screening Visit will coincide with the last visit of the Maintenance Period in the Parent Study 2) Extended Treatment Period 3) Post-treatment Follow-up Period.
This study will be conducted in participants with atopic dermatitis (AD) who completed the Treatment Period in a prior APG777 study and who, in the opinion of the Investigator, would benefit from long-term treatment with APG777.
1,591 studies on the registry are indexed under Dermatitis, Atopic; 286 are open to participants now.
This study's planned enrollment of 350 is above the median of 82 across 1,246 interventional studies indexed under Dermatitis, Atopic.
Browse Dermatitis, Atopic studies →Apogee Therapeutics, Inc. is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
First submitted before Apogee Therapeutics, Inc. became part of AbbVie.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Note: Additional protocol defined Inclusion/Exclusion criteria may apply
Participants who achieve EASI 75 or a vIGA-AD (0, 1) at the end of the Parent Study Treatment Period, and who did not use topical rescue medication during the Parent Study will maintain the same dose regimen (dose and frequency of injections) from the Maintenance Period of the Parent Study (APG777-201).
Drug: APG777
Participants who achieve EASI 75 or a vIGA-AD (0, 1) at the end of the Parent Study Treatment Period, and who did not use topical rescue medication during the Parent Study, will maintain the same dose regimen (dose and frequency of injections) from the Maintenance Period of the Parent Study (APG777-201).
Drug: APG777
Participants who do not achieve EASI 75 or a vIGA-AD (0, 1) at the end of the Parent Study Treatment Period, or who used topical rescue medication during the Parent Study, will be assigned to the open-label Escape Arm and will receive APG777 per protocol defined dosing regimen.
Drug: APG777
Number of Participants with Treatment Emergent Adverse Events
Time frame: Up to 3 years
Percentage of Participants who achieve Eczema Area and Severity Index (EASI) 50, 75, 90, and 100 calculated based on Parent Study Baseline
Time frame: Through Extended Treatment Period, an average of 2 years
Percentage of Participants who achieve a validated Investigator Global Assessment Atopic Dermatitis (vIGA AD) score of 0 (clear) or 1 (almost clear) and a ≥ 2-point reduction as calculated based on Parent Study Baseline.
Time frame: Through Extended Treatment Period, an average of 2 years
Percentage of Participants who achieve ≥ 4-point improvement in the weekly mean of the daily Itch Numeric Rating Scale (I-NRS) as calculated based on Parent Study Baseline
Time frame: Through Extended Treatment Period, an average of 2 years
Percentage of Participants who use Rescue Therapy
Time frame: Through Extended Treatment Period, an average of 2 years
Percentage of Participants Who Continue to Exhibit EASI 75
Of the participants who achieve EASI 75 at Week 52 of the Parent Study, the percentage that continue to exhibit EASI 75 will be determined
Time frame: From Week 52 up to Through Extended Treatment Period, an average of 2 years
Percentage of Participants Who Continue to Exhibit vIGA-AD Response
Of the participants who achieve vIGA-AD of clear (0) or almost clear (1) and a ≥ 2-Point reduction at Week 52 of the Parent Study, the percentage that continue to exhibit the response will be determined.
Time frame: From Week 52 up to Through Extended Treatment Period, an average of 2 years
Percentage of Participants Who Continue to Exhibit I-NRS Response
Of the participants who achieve a ≥ 4 point improvement in the weekly mean of the daily I NRS at Week 52 of the Parent Study, the percentage that continue to exhibit the response will be determined.
Time frame: From Week 52 up to Through Extended Treatment Period, an average of 2 years
Number of Participants who Discontinued Treatment Due to Treatment-Related TEAEs and SAEs
Time frame: Up to 3 years
Serum Concentrations of APG777 Over Time
Time frame: Up to 3 years
Predose Serum Concentrations of APG777
Time frame: Up to 3 years
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zumilokibart